1. Scrip
  2. >>Focus On Asia
  3. >>India

INTERVIEW: Hilleman CEO On $1 Rotavirus Vaccine Challenges

 
• By Anju Ghangurde

Hilleman Laboratories' CEO, Dr. Davinder Gill, believes that the venture's heat-stable rotavirus vaccine can potentially match the proposed $1 pricing of Bharat Biotech's Rotavac backed with "appropriate scale" and a robust demand forecast.

India’s Hilleman Laboratories has developed a new low-cost vaccine for rotavirus that it sees able to compete with the $1 a dose pricing of Rotavac, a rival product from Bharat Biotech International Ltd.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia